NON-INVASIVE PREDICTORS OF MAINTAINING REMISSION IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH TOFACITINIB WHO DOSE-REDUCED FROM TOFACITINIB 10 MG TWICE DAILY TO 5 MG TWICE DAILY: 6-MONTH DATA FROM THE DOUBLE-BLIND, RANDOMISED RIVETING STUDY
Geert R. D'Haens 1
Genoile O. Santana 2
William J. Sandborn 3
Irene Modesto 4
Chinyu Su 5
Nervin Lawendy 5
Jerome Paulissen 4
Marla C. Dubinsky 6
Miguel Regueiro
nicole kulisek
Sean Gardiner
Rajiv Mundayat
Joana Torres
1 Amsterdam University Medical Centres,Amsterdam,Netherlands
2 University of the State of Bahia,Salvador,Brazil
3 University of California San Diego,La Jolla,United States
4 Pfizer Inc,New York,United States
5 Pfizer Inc,Collegeville,United States
6 Icahn School of M
Session
IBD (Posters)
Conference
UEG Week Virtual 2021
Citation
United European Gastroenterology Journal 2021; 9 (Supplement 1)
Login to access library content
Do you need help setting up your myUEG account?
Contact us at [email protected]